SAN DIEGO, April 22, 2015 /PRNewswire/ -- Edico Genome, developer of the world's first Bio-IT Processor, DRAGEN™, a solution that enables fast and cost-effective analysis of next-generation sequencing (NGS) data, today announced the United States Patent and Trademark Office has issued to the company U.S. patent number 9,014,989. This patent broadly covers proprietary processes that are core to DRAGEN, including bioinformatics protocols and functions necessary for the analysis of genomic data on integrated circuits and hardware processing platforms. The patent will provide protection until 2035 and is entitled "Bioinformatics Systems, Apparatuses, and Methods Executed on an Integrated Circuit Processing Platform."
DRAGEN is a reconfigurable processor that is loaded with highly optimized algorithms for analysis of NGS data, including reference-based mapping, aligning, sorting, deduplication and variant calling. This approach has been shown to reduce analysis times from hours to minutes, while decreasing the need for clusters of large servers to process the data, which lowers costs related to storage space and IT infrastructure.
"This foundational patent, anticipated to be the first of many as Edico accumulates a sizeable patent portfolio, provides robust protection for our proprietary DRAGEN Bio-IT Processor," said Pieter van Rooyen, Ph.D., Chief Executive Officer of Edico Genome. "Strong patent protection is also seen favorably by potential partners, and the issuance of this patent can further facilitate our ability to form partnerships such as our recently announced collaboration with Intel to develop solutions with their Xeon processors that accelerate NGS data analysis."
About the DRAGEN Bio-IT Processor
DRAGEN™, the world's first next-generation sequencing (NGS) Bio-IT processor, is a reconfigurable platform designed to massively accelerate secondary analysis of NGS while simultaneously improving accuracy, removing a key bottleneck in NGS workflow. DRAGEN is loaded with highly optimized algorithms for mapping, alignment, sorting and variant calling, and the flexible platform can be loaded with additional algorithms for a range of secondary analysis pipelines, such as whole genome or exome, RNAseq, methylome, microbiome and cancer. The solution can be integrated directly into NGS bioinformatics servers and sequencing instruments and is provided with accompanying software as a Platform-as-a-Service (PaaS). Interested parties may inquire about DRAGEN at http://www.edicogenome.com/dragen/get-dragen-now/.
About Edico Genome
Edico Genome, developer of the world's first next-generation sequencing Bio-IT processor, DRAGEN™, is helping usher in the new era of precision medicine by enabling customized treatments and data-driven insights tailored to the individual. At the heart of personalized medicine is next-generation sequencing (NGS), which is growing at an unprecedented pace. By increasing the speed and accuracy of NGS data analysis, such as whole genome sequencing, Edico Genome's computing platform makes it easier to discover links between DNA sequence variations and human disease, allowing clinicians and researchers to reveal answers more quickly. For more information, visit www.EdicoGenome.com and follow #DRAGENonFIRE.
SOURCE Edico Genome